The Follicle-stimulating Hormone Receptor: a Novel Target in Genitourinary Malignancies

Overview

Journal Urol Oncol

Publisher Elsevier

Date 2012 Apr 20

PMID 22513137

Citations 13

Authors

Benjamin A Gartrell

Che-Kai Tsao

Matthew D Galsky

Affiliations

Soon will be listed here.

Abstract

Follicle-stimulating hormone (FSH) is a central hormone in mammalian reproductive biology. The FSH receptor (FSHR), which was previously believed to be expressed primarily in the ovary and testis, was recently found to be expressed in the tumor blood vessels of many solid tumor types, including prostate adenocarcinoma, urothelial carcinoma, and renal cell carcinoma. While the biologic significance of FSHR in tumor blood vessels has yet to be elucidated, FSHR may contribute to neoangiogenesis. FSHR has been reported to be expressed by prostate cancer cells and, thus, targeting FSHR in prostate cancer may be of particular utility. In this report, we discuss the finding of FSHR in tumor blood vessels and review the literature concerning FSHR in genitourinary malignancy. We also discuss the features that make FSHR an appealing target for therapeutic and imaging purposes and the potential utility of FSHR as a prognostic and/or predictive biomarker in genitourinary cancers.

Citing Articles

Extra-Gonadal and Non-Canonical Effects of FSH in Males.

Spaziani M, Carlomagno F, Tenuta M, Sesti F, Angelini F, Bonaventura I Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375761 PMC: 10300833. DOI: 10.3390/ph16060813.

A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [F]fluoride: Will [F]AlF Replace Ga for Metal Chelate Labeling?.

Fersing C, Bouhlel A, Cantelli C, Garrigue P, Lisowski V, Guillet B Molecules. 2019; 24(16).

PMID: 31394799 PMC: 6719958. DOI: 10.3390/molecules24162866.

Small Molecule Follicle-Stimulating Hormone Receptor Agonists and Antagonists.

Anderson R, Newton C, Millar R Front Endocrinol (Lausanne). 2019; 9:757.

PMID: 30728807 PMC: 6352558. DOI: 10.3389/fendo.2018.00757.

Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer.

Porcaro A, Siracusano S, De Luyk N, Corsi P, Sebben M, Tafuri A Curr Urol. 2017; 10(4):174-181.

PMID: 29234259 PMC: 5704728. DOI: 10.1159/000447177.

Parity History Determines a Systemic Inflammatory Response to Spread of Ovarian Cancer in Naturally Aged Mice.

Urzua U, Chacon C, Lizama L, Sarmiento S, Villalobos P, Kroxato B Aging Dis. 2017; 8(5):546-557.

PMID: 28966800 PMC: 5614320. DOI: 10.14336/AD.2017.0110.

References

van Straten N, van Berkel T, Demont D, Karstens W, Merkx R, Oosterom J . Identification of substituted 6-amino-4-phenyltetrahydroquinoline derivatives: potent antagonists for the follicle-stimulating hormone receptor. J Med Chem. 2005; 48(6):1697-700. DOI: 10.1021/jm049676l. View

La Marca A, Artenisio A, Stabile G, Rivasi F, Volpe A . Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium. Gynecol Endocrinol. 2006; 21(6):303-6. DOI: 10.1080/09513590500402756. View

Dirnhofer S, Berger C, Hermann M, Steiner G, Madersbacher S, Berger P . Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate. 1998; 35(3):212-20. DOI: 10.1002/(sici)1097-0045(19980515)35:3<212::aid-pros7>3.0.co;2-i. View

Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A . Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010; 363(17):1621-30. DOI: 10.1056/NEJMoa1001283. View

Vannier B, Loosfelt H, Meduri G, Pichon C, Milgrom E . Anti-human FSH receptor monoclonal antibodies: immunochemical and immunocytochemical characterization of the receptor. Biochemistry. 1996; 35(5):1358-66. DOI: 10.1021/bi952290f. View

Crawford E, Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N . A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011; 186(3):889-97. DOI: 10.1016/j.juro.2011.04.083. View

Olumi A, Grossfeld G, Hayward S, Carroll P, Tlsty T, Cunha G . Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999; 59(19):5002-11. PMC: 3300837. DOI: 10.1186/bcr138. View

Plant T, Marshall G . The functional significance of FSH in spermatogenesis and the control of its secretion in male primates. Endocr Rev. 2001; 22(6):764-86. DOI: 10.1210/edrv.22.6.0446. View

Danesi R, La Rocca R, Cooper M, Ricciardi M, Pellegrini A, Soldani P . Clinical and experimental evidence of inhibition of testosterone production by suramin. J Clin Endocrinol Metab. 1996; 81(6):2238-46. DOI: 10.1210/jcem.81.6.8964858. View

10.

Arey B, Yanofsky S, Perez M, Holmes C, Wrobel J, Gopalsamy A . Differing pharmacological activities of thiazolidinone analogs at the FSH receptor. Biochem Biophys Res Commun. 2008; 368(3):723-8. DOI: 10.1016/j.bbrc.2008.01.119. View

11.

Beer T, Garzotto M, Eilers K, Lemmon D, Wersinger E . Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. Urology. 2004; 63(2):342-7. DOI: 10.1016/j.urology.2003.09.045. View

12.

Hai M, Lescop P, Loosfelt H, Ghinea N . Receptor-mediated transcytosis of follicle-stimulating hormone through the rat testicular microvasculature. Biol Cell. 2004; 96(2):133-44. DOI: 10.1016/j.biolcel.2003.11.008. View

13.

Macklon N, Fauser B . Follicle development during the normal menstrual cycle. Maturitas. 1999; 30(2):181-8. DOI: 10.1016/s0378-5122(98)00072-3. View

14.

Daugherty R, COCKETT A, Schoen S, Sluss P . Suramin inhibits gonadotropin action in rat testis: implications for treatment of advanced prostate cancer. J Urol. 1992; 147(3):727-32. DOI: 10.1016/s0022-5347(17)37367-6. View

15.

Franci C, Takkunen M, Dave N, Alameda F, Gomez S, Rodriguez R . Expression of Snail protein in tumor-stroma interface. Oncogene. 2006; 25(37):5134-44. DOI: 10.1038/sj.onc.1209519. View

16.

Zheng W, Magid M, KRAMER E, Chen Y . Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol. 1996; 148(1):47-53. PMC: 1861603. View

17.

Voulgari A, Pintzas A . Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009; 1796(2):75-90. DOI: 10.1016/j.bbcan.2009.03.002. View

18.

Ben-Josef E, Yang S, Ji T, Bidart J, Garde S, Chopra D . Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol. 1999; 161(3):970-6. View

19.

Wrobel J, Green D, Jetter J, Kao W, Rogers J, Perez M . Synthesis of (bis)sulfonic acid, (bis)benzamides as follicle-stimulating hormone (FSH) antagonists. Bioorg Med Chem. 2002; 10(3):639-56. DOI: 10.1016/s0968-0896(01)00324-8. View

20.

Dias J, Bonnet B, Weaver B, Watts J, Kluetzman K, Thomas R . A negative allosteric modulator demonstrates biased antagonism of the follicle stimulating hormone receptor. Mol Cell Endocrinol. 2010; 333(2):143-50. PMC: 4491433. DOI: 10.1016/j.mce.2010.12.023. View